The antiplasmodial activity of norcantharidin analogs.

USDA, ARS, Natural Products Utilization Research Unit, University, MS 38677, USA.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.65). 09/2010; 20(22):6688-95. DOI: 10.1016/j.bmcl.2010.09.004
Source: PubMed

ABSTRACT The antiplasmodial activities of sixty norcantharidin analogs were tested in vitro against a chloroquine sensitive (D6, Sierra Leone) and chloroquine resistant (W2) strains of Plasmodium falciparum. Forty analogs returned IC(50) values <500 μM against at least one of the P. falciparum strains examined. The ring open compound 24 ((1S,4R)-3-(allylcarbamoyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid) is the most active aliphatic analog (D6 IC(50)=3.0±0.0 and W2 IC(50)=3.0±0.8 μM) with a 20-fold enhancement relative to norcantharidin. Surprisingly, seven norcantharimides also displayed good antiplasmodial activity with the most potent, 5 returning D6=8.9±0.9 and W2 IC(50)=12.5±2.2 μM, representing a fivefold enhancement over norcantharidin.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cantharidin, a natural toxin produced by the blister beetle, was reported to be toxic to some pests, but the mechanism of its toxicity in insects remains undefined. We found that cantharidin exerted in vivo and in vitro inhibitory effects on protein serine/threonine phosphatases (PSPs) of Plutella xylostella. Five PSP genes, PP1, PP2A, PP4, PP5, and PP6, were cloned from P. xylostella. Phosphatase domain alignment showed a high similarity. Recombinant PxPP5 (rPxPP5) was expressed in Escherichia coli and purified. Cantharidin and its 11 analogs were used to perform the rPxPP5 activity inhibition assay in vitro. Cantharidin strongly inhibited rPxPP5 activity competitively, with an IC50 of 0.38 μM. All analogs also showed inhibitory activity, with an IC50 of 7.42-538.38 μM. The rank of IC50 values was found to be consistent with their toxicities in P. xylostella larvae with a correlation coefficient (R(2)) of 0.87. 3D models of the phosphatase domains of these five PxPSPs were constructed which superimposed well indicating a high structural similarity demonstrating that the chemicals used may be inhibitors of the other four PxPSPs. Binding model analysis of cantharidin and its analogs which interacted with PxPP5 showed that the cantharidin-derived moiety was anchored to the active site, explaining their inhibitory effect on rPxPP5 in vitro. Results of binding free energy calculations are also well in line with their inhibition effects on rPxPP5, with a correlation coefficient (R(2)) of 0.72. In light of the above results we argue that protein serine/threonine phosphatases are the targets of cantharidin and its analogs acting on P. xylostella.
    Molecular BioSystems 11/2013; · 3.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemical and pharmacological information on cantharidin-based SMs was analyzed. The review summarizes new facts about blister beetles metabolites for the period 2006-2012. General synthetic approaches to cantharidin-based small molecules as well as its chemical transformations and the biological activities related with cantharidin, norcantharidin, cantharidimide and norcantharimide analogues, specially their inhibitory activity of phosphoprotein phosphatases in cancer treatment, were discussed in this mini review that could help to design new small molecules modulators for other biological models. This article is protected by copyright. All rights reserved.
    Chemical Biology &amp Drug Design 06/2013; · 2.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Except for honey as food, and silk for clothing and pollination of plants, people give little thought to the benefits of insects in their lives. This overview briefly describes significant recent advances in developing insect natural products as potential new medicinal drugs. This is an exciting and rapidly expanding new field since insects are hugely variable and have utilised an enormous range of natural products to survive environmental perturbations for 100s of millions of years. There is thus a treasure chest of untapped resources waiting to be discovered. Insects products, such as silk and honey, have already been utilised for thousands of years, and extracts of insects have been produced for use in Folk Medicine around the world, but only with the development of modern molecular and biochemical techniques has it become feasible to manipulate and bioengineer insect natural products into modern medicines. Utilising knowledge gleaned from Insect Folk Medicines, this review describes modern research into bioengineering honey and venom from bees, silk, cantharidin, antimicrobial peptides, and maggot secretions and anticoagulants from blood-sucking insects into medicines. Problems and solutions encountered in these endeavours are described and indicate that the future is bright for new insect derived pharmaceuticals treatments and medicines.
    Evidence-based Complementary and Alternative Medicine 01/2014; 2014:904958. · 2.18 Impact Factor


Available from
Oct 1, 2014